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Background:  Recent  studies  have  suggested  that  vaccine-induced  protection  against  inﬂuenza  may  decline
within  one  season.  We  reanalyzed  data  from  a  study  of  inﬂuenza  vaccine  effectiveness  to  determine  if
time  since  vaccination  was  an  independent  predictor  of  inﬂuenza  A  (H3N2).
Methods:  Patients  with  acute  respiratory  illness  were  actively  recruited  during  the  2007–2008  season.
Respiratory  swabs  were  tested  for inﬂuenza,  and  vaccination  dates  were  determined  by a  validated  immu-
nization registry.  The  association  between  inﬂuenza  RT-PCR  result  and  vaccination  interval  (days)  was
examined  using  multivariable  logistic  regression,  adjusting  for calendar  time,  age  and  other  confounders.
Results:  There  were  629  vaccinated  participants,  including  177  inﬂuenza  A  (H3N2)  cases  and  452 test
negative  controls.  The  mean  (SD)  interval  from  vaccination  to  illness  onset  was  101.7  (25.9)  days  for
inﬂuenza  cases  and  93.0  (29.9)  days  for  controls.  There  was  a  signiﬁcant  association  between  vaccination
interval  and  inﬂuenza  result  in  the  main  effects  model.  The  adjusted  odds  ratio (aOR)  for  inﬂuenza  was
1.12  (CI  1.01,  1.26)  for every  14  day  increase  in the  vaccination  interval.  Age  modiﬁed  the  association
between  vaccination  interval  and  inﬂuenza  (p =  0.005  for  interaction).  Inﬂuenza  was  associated  with
increasing  vaccination  interval  in young  children  and  older  adults,  but  not  in  adolescents  or non-elderly
adults.  Similar  results  were found  when  calendar  week  of  vaccine  receipt  was assessed  as the  primary
exposure  variable.
Conclusions:  Identiﬁcation  of  inﬂuenza  A  (H3N2)  was associated  with  increasing  time  since  vaccination
d  old
ublisamong  young  children  an
© 2014  The  Authors.  P
. Introduction
Annual inﬂuenza vaccination is a key component of inﬂuenza
revention and control efforts in the United States. In most seasons,
rivalent inactivated inﬂuenza vaccine (TIV) provides moderate
rotection against inﬂuenza illness in healthy adults [1], and a
emagglutination inhibition (HI) titer of 1:40 or greater has been
ssociated with clinical protection [2–4]. A systematic review of
ublished studies found that seroprotective titers against inﬂuenza were maintained for >4 months after immunization in almost all
tudies [5], but recent reports have raised concerns that vaccine
Abbreviations: HI, hemagglutinin antibody inhibition; TIV, trivalent inactivated
nﬂuenza vaccine; RT-PCR, reverse transcription polymerase chain reaction; NK,
atural killer; ACIP, Advisory Committee on Immunization Practices.
∗ Corresponding author. Tel.: +1 715 389 3783; fax: +1 715 389 3880.
E-mail address: belongia.edward@marshﬁeldclinic.org (E.A. Belongia).
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.052
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uner  adults  during  a single  inﬂuenza  season.
hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
induced protection against inﬂuenza illness may decline over the
course of a single season [6–8].
The goal of this study was to assess evidence for waning pro-
tection against inﬂuenza A (H3N2) in a community cohort. To do
this, we  reanalyzed data from an observational study of inﬂuenza
vaccine effectiveness that was performed during the 2007–2008
inﬂuenza season. Vaccine effectiveness against inﬂuenza A (H3N2)
was 41% in the study population during that season [9]. The Marsh-
ﬁeld Clinic Research Foundation has conducted annual assessments
of inﬂuenza vaccine effectiveness in Wisconsin since 2005, but this
analysis focused on the 2007–2008 season because the number
of inﬂuenza A (H3N2) cases was substantially higher compared to
other seasons.2. Methods
The source population included community-dwelling residents
≥6 months old living in or near Marshﬁeld, Wisconsin [10]. Patients
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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n this population were screened and enrolled by trained research
oordinators during or after an encounter for acute respiratory
llness with symptoms of feverishness, chills, or cough. Potential
articipants with illness duration >7 days were excluded to mini-
ize false negative inﬂuenza test results. Enrollment occurred in
rimary care departments at the Marshﬁeld Clinic main campus, a
earby satellite clinic, and an acute care hospital.
Each participant or parent was interviewed to determine ill-
ess onset date. Nasopharyngeal (adults and adolescents) or nasal
wabs (children < 12 years) were obtained and tested for inﬂuenza
y reverse transcription polymerase chain reaction (RT-PCR). Par-
icipants were classiﬁed as having a high-risk health condition if
hey had ≥2 medical visits during 2007 with a relevant ICD-9 diag-
osis code (list of codes available on request).
Enrollment in the study began on January 21, 2008 based on
aboratory identiﬁcation of inﬂuenza at the local clinical labora-
ory and the Wisconsin State Laboratory of Hygiene. Enrollment
ontinued for 10 weeks, ending on March 28, 2008.
.1. Laboratory methods
Swabs were placed in M4-RT viral transport media and deliv-
red to the Marshﬁeld Clinic Research Foundation laboratory on
he same day. Samples were routinely processed within one day,
nd weekend samples were tested on Monday. Nucleic acid was
xtracted using the Roche MagNA Pure Total Nucleic Acid Kit (Roche
iagnostics, Indianapolis, Indiana), and RT-PCR was  performed
sing the LightCycler® Real-Time PCR System (Roche Diagnostics,
asel, Switzerland). The U.S. Centers for Disease Control and Pre-
ention provided sequence information for RT-PCR primers and
robes. The TaqMan®-based RT-PCR assay detects two  highly-
onserved inﬂuenza genes: the matrix gene of inﬂuenza A and the
on-structural gene of inﬂuenza B. A human RNase P gene served
s a positive control for human nucleic acid. Virus subtyping by
T-PCR was performed on all samples with a positive inﬂuenza A
esult.
.2. Inﬂuenza vaccination status and dates
Vaccination status and dates were determined by a real-time,
nternet-based registry used by all immunization providers serving
he local population (www.recin.org). The capture of the registry
as validated during the 2006–2007 and 2007–2008 inﬂuenza sea-
ons, and after adjudication it was found that the registry captured
5% of all inﬂuenza vaccinations received by study participants [11].
or this analysis, participants were considered immunized if a dose
f vaccine was received ≥14 days before illness onset. Children
nder the age of nine were recommended to receive two  doses of
nﬂuenza vaccine. Partially vaccinated children who  received only
ne of two recommended doses were excluded from the analysis.
or fully vaccinated children, the most recent dose received prior
o illness onset was used to determine the interval from vaccina-
ion to illness. Only trivalent inactivated vaccine was  evaluated, and
he Marshﬁeld Clinic did not administer live attenuated inﬂuenza
accine during the 2007–2008 season.
The study was approved by the Marshﬁeld Clinic Institutional
eview Board and all participants provided written informed con-
ent.
.3. Analytic approach
We  tested the hypothesis that RT-PCR conﬁrmed inﬂuenza A
as independently associated with a longer interval from inﬂuenza
accination to illness onset after adjustment for calendar time,
ge and other potential confounders. The analyses were restricted
o vaccinated adults and children because a vaccination interval 33 (2015) 246–251 247
cannot be calculated for unvaccinated individuals. We  did not
attempt to directly calculate vaccine effectiveness for different
vaccination intervals because it would require inclusion of the
unvaccinated group, and the precision of vaccine effectiveness esti-
mates was expected to be low for time windows before and after
the epidemic peak. In contrast, the analysis of vaccination intervals
allowed for detection of small differences in time from vaccination
to illness onset for cases and controls after adjusting for the effect
of calendar time and age.
The outcome variable was a positive RT-PCR test result for
inﬂuenza A (H3N2) (cases) vs. a negative result (test negative con-
trols). We  excluded individuals with inﬂuenza B infection because
there were relatively few cases of inﬂuenza B, and differences in
the temporal occurrence of inﬂuenza A and B could be a source of
confounding. Although the study design allowed multiple enroll-
ments per person for distinct illness episodes, we  included only the
ﬁrst enrollment for each person unless inﬂuenza was detected on
a subsequent enrollment. In that case, we  included the inﬂuenza
positive enrollment and excluded other enrollments for the same
person. We  also repeated the primary analysis after exclusion of all
individuals with multiple enrollments to ensure that results were
not biased by including inﬂuenza infections that occurred during a
second illness episode.
The multivariable logistic regression model assessed the associ-
ation between vaccination interval (days from vaccination to illness
onset) and probability of inﬂuenza. The main predictor was the
interval (days) from vaccination to illness onset. The relationship
between age and inﬂuenza result was  nonlinear (Supplemental Fig-
ure S1), and we included covariates for age and age squared in the
model. The timing of illness onset was analyzed as a series of indi-
cator variables representing 2 week time periods in the model. Each
period was  compared to the referent period of weeks 7–8 (repre-
senting the peak of inﬂuenza occurrence in the community).
We examined the association between vaccination interval
and inﬂuenza using two different models. A main effects model
included the primary exposure (days from vaccination to illness
onset) and potential confounders. These included sex, interval
between illness onset and enrollment (days), and presence or
absence of a high-risk health condition. Effect modiﬁcation was
examined with the addition of interaction terms for vaccination
interval (days) and each covariate. Each interaction term was evalu-
ated separately, and covariate and interaction terms were included
in the ﬁnal reduced model if they were signiﬁcantly associated with
inﬂuenza (p < 0.05) or changed the point estimate for the primary
exposure by more than 10%. Since age was  modeled as a continuous
variable in this analysis, we used the model results to illustrate the
relationship between vaccination interval and log-odds of inﬂuenza
at six arbitrarily selected ages.
We  performed a secondary analysis using calendar week of
inﬂuenza vaccine receipt rather than vaccination interval as the
exposure of interest. The model covariates were the same as in the
primary analysis. All analytical procedures were conducted using
SAS version 9.2 (SAS Institute, Cary, NC).
3. Results
There were 1972 enrollments representing 1955 unique
patients during the 2007–2008 inﬂuenza season. For the analy-
sis of waning protection against inﬂuenza A (H3N2), we excluded
study participants with inﬂuenza B (n = 233), unvaccinated indi-
viduals (n = 1088), and ﬁve participants who received inﬂuenza
vaccine within 14 days before illness onset. During this season
there were an additional 17 individuals (<1%) who  were enrolled
twice for independent illness episodes, including 4 who were pos-
itive for inﬂuenza during the second enrollment only. The second
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Fig. 1. Number of inﬂuenza positives and negatives by week of vaccination, according to age.
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B) Adults 18–64 years old.
C) Adults ≥65 years old.
nrollment was included in the analysis for those four individuals
nd the ﬁrst enrollment was used for the other 13. The ﬁnal anal-
sis included 629 vaccinated study participants; 599 (95%) were
nrolled in the outpatient setting and 30 (5%) were enrolled as
npatients.
Vaccination dates ranged from 10/1/2007 (week 40) to 3/4/2008
week 10); vaccine administration peaked in mid-November 2007.
he mean age (±SD) was 30.6 (±27.9) years, and the mean interval
rom illness onset to enrollment was 3.3 (±1.9) days. There were
77 (28%) inﬂuenza A cases conﬁrmed by RT-PCR. Study enrollment
as initiated in January before inﬂuenza activity increased in the
ommunity, and the epidemic peak occurred in February (Supple-
ental Figure S2). Fig. 1 shows the number of inﬂuenza positives
nd negatives by week of vaccination in different age groups.Inﬂuenza cases and test negative controls differed signiﬁcantly
by age, interval from vaccination to illness onset, interval from
study initiation (January 21) to illness onset, and timing of illness
onset relative to the epidemic peak (Table 1). The median date
of vaccination was November 6, 2007 for those with RT-PCR con-
ﬁrmed inﬂuenza and November 12, 2007 for test negative controls.
In the univariate analysis, inﬂuenza A (H3N2) was  signiﬁcantly
associated with the interval (days) from vaccination to illness
onset. The unadjusted odds ratio for inﬂuenza was 1.16 (CI 1.06,
1.27; p = 0.001) for every 14 day increase in the vaccination inter-
val. There was also a signiﬁcant association between inﬂuenza
and interval from vaccination to illness onset in the main effects
model without interaction terms. The adjusted odds ratio (aOR)
for inﬂuenza was  1.12 (CI 1.01, 1.26) for every 14 day increase
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Table  1
Demographic and clinical features of study participants with RT-PCR conﬁrmed inﬂuenza A (H3N2) (cases) and non-inﬂuenza respiratory illness (controls) who  received
inﬂuenza vaccine at least 14 days before illness onset.
Characteristic Vaccinated cases (N = 177) Vaccinated test negative controls (N = 452) P-valuea
Age, years, N (%)
0–2 18 (10.2) 113 (25.0) 0.0004
3–5  23 (13.0) 59 (13.1)
6–20 21 (11.9) 56 (12.4)
21–50 57 (32.2) 94 (20.8)
51–65 26 (14.7) 68 (15.0)
66–75 19 (10.7) 26 (5.8)
>75  13 (7.3) 36 (8.0)
Male, N (%) 77 (43.5) 197 (43.6) 0.99
High  risk condition, N (%) 53 (29.9) 134 (29.7) 0.94
Illness onset to swab interval, days (mean ± SD) 3.0 ± 1.8 3.4 ± 2.0 0.005
Vaccination to illness onset interval, days (mean ± SD) 101.7 ± 25.9 93.0 ± 29.9 0.0008
Study  onset to illness onset interval, days (mean ± SD) 30.5 ± 15.7 26.7 ± 18.6 0.02
MMWR  week of vaccine receipt (mean ± SD) 45.6 ± 3.3 46.3 ± 3.7 0.03
Illness onset period: N (%)
Inﬂuenza peak period (Feb 3–Mar 1) 114 (64.4) 207 (45.8) <0.0001
Pre-peak period (Jan 14–Feb 2) 22 (12.4) 125 (27.7)
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pPost-peak period (Mar 2–Mar 27) 41 (23.2)
a P-values shown are chi-square or t-test values for categorical or continuous var
n the vaccination interval. In the primary multivariable model
hat included signiﬁcant interactions, inﬂuenza was  independently
ssociated with illness onset week, interval from illness onset to
nrollment, age (quadratic function represented by age and age
quared), and interval from vaccination to illness onset (Table 2).
ffect modiﬁcation by age was observed with signiﬁcant interaction
erms for age-by-vaccination interval (p = 0.005) and age-squared-
y-vaccination interval (p = 0.005). There were no other signiﬁcant
nteractions. The association between vaccination interval and
nﬂuenza was nearly identical in the main effects model after
xcluding the 17 individuals who were each enrolled twice, and the
ame effect modiﬁcation by age was observed (data not shown).
Since age was included in the model as a continuous vari-
ble, we arbitrarily selected six different ages to illustrate the
bserved association between increasing vaccination interval and
dds of inﬂuenza (Fig. 2). This demonstrated that individuals at the
xtremes of age had greater odds of inﬂuenza with increasing vac-
ination interval, but this effect was not observed for older children
r non-elderly adults.
able 2
ultivariable logistic regression model for conﬁrmed inﬂuenza A (H3N2) and days from 
ith  inclusion of all variables signiﬁcantly associated with inﬂuenza (p < 0.05).
Model parameters RT-PCR conﬁr
Ba
Intercept –2.022 
Illness  onset week
1–2 –14.355 
3–4  –0.773 
5–6  0.021 
7–8  Ref 
9–10  –0.820 
11–12  –0.356 
Days  from illness onset to enrollment –0.130 
Age  (years) 0.166 
Age-squared –0.002 
Vaccination interval (days)b 0.015 
Interaction: Vaccination interval × Age –0.001 
Interaction: Vaccination interval × Age-squared <0.001
a B values are equal to (natural) logarithmic odds ratio of RT-PCR conﬁrmed inﬂuenza
redictor variable changes (relative to the reference category for categorical predictors or a
 increases. Negative values indicate that as the predictor variable changes (relative to th
redictors), the odds of RT-PCR conﬁrmed inﬂuenza A decreases.
b Vaccination interval = number of days from vaccination to illness onset.120 (26.6)
, respectively.
To minimize the potential for disease misclassiﬁcation (false
negative RT-PCR), we performed a sensitivity analysis that excluded
161 patients who  were enrolled ≥5 days after illness onset. Results
were similar to the primary analysis, and signiﬁcant effect mod-
iﬁcation between age and vaccination interval was observed. We
also performed a sensitivity analysis that excluded 30 individuals
who were enrolled as hospital inpatients, since the relationship
between vaccination interval and inﬂuenza may  not be the same
for outpatients and inpatients. When the analysis was restricted
to outpatient enrollments, the results were nearly identical to
the primary analysis that included all participants, and signiﬁcant
effect modiﬁcation between age and vaccination interval was  still
present.
We repeated the primary analysis with calendar week of vacci-
nation as the exposure of interest rather than vaccination interval.
In this analysis, the exposure was  based entirely on calendar time
and differences in the date of illness onset did not affect the expo-
sure variable (although the model adjusted for timing of illness
onset). Results from this multivariable model were similar to those
vaccination to illness onset (primary exposure). The ﬁnal reduced model is shown
med inﬂuenza A (H3N2)
OR CI p
– – 0.002
0.000 0.000, >999.0 0.975
0.461 0.254, 0.837 0.011
1.021 0.634, 1.644 0.933
Ref Ref Ref
0.441 0.246, 0.789 0.006
0.701 0.351, 1.401 0.314
0.878 0.796, 0.970 0.010
1.181 1.068, 1.305 0.001
0.998 0.996, 0.999 0.002
1.016 1.003, 1.028 0.016
0.999 0.998, 1.000 0.005
1.000 1.000, 1.000 0.005
 A infection relative to the reference category. Positive values indicate that as the
 1-unit increase for continuous predictors), the odds of RT-PCR conﬁrmed inﬂuenza
e reference category for categorical predictors or a 1-unit increase for continuous
250 E.A. Belongia et al. / Vaccine
Fig. 2. Adjusted odds ratios and 95% conﬁdence intervals for inﬂuenza A positive
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Fesult per 14 day increase in vaccination interval at selected ages. Models were
djusted for calendar time (illness onset week) and interval from illness onset to
wab collection.
rom the primary analysis. Inﬂuenza vaccinations received during
arlier weeks were associated with a higher odds of inﬂuenza com-
ared to vaccinations received during later weeks after adjustment
or potential confounders. A signiﬁcant interaction was observed
etween vaccination week and age.
. Discussion
In this study we identiﬁed a signiﬁcant association between
nﬂuenza A (H3N2) positive medically attended ARI visits and
ncreasing time since vaccination among young children and
lderly adults. The magnitude of the effect was modest, and it was
bserved only at the extremes of age. For example, the adjusted
dds of inﬂuenza increased by 1.2 for each two week increase in
he vaccination interval in two year old children. Similarly, for a 75
ear old adult, the odds of inﬂuenza increased by 1.3 for each two
eek increase in the vaccination interval. We  did not see any sig-
iﬁcant association between inﬂuenza and vaccination interval in
lder children, adolescents, and non-elderly adults. We  observed a
imilar association between calendar week of vaccination and risk
f inﬂuenza, with the highest risk in people who were vaccinated
arlier in the season. These results are consistent with a linear rela-
ionship between vaccination interval and risk of inﬂuenza, at least
t the extremes of age, although we cannot rule out a nonlinear
elationship with a threshold effect.
The increasing risk of inﬂuenza over time may  be related
o changes in host immune response or a combination of
ost and virus-related characteristics. The H3N2 component
f the 2007–2008 northern hemisphere inﬂuenza vaccine was
/Wisconsin/67/2005-like, and a minor antigenic variant (distinct
rom the vaccine strain) was identiﬁed in the United States and
ur study population. In the United States, this minor variant
A/Brisbane/10/2007-like) comprised 71% of A (H3N2) viruses
haracterized in 2007–2008, (http://www.cdc.gov/ﬂu/weekly/
eeklyarchives2007-2008/weekly14.htm). This variant was
resent in 14 of 24 viruses that were evaluated from study partici-
ants. All but one of the characterized viruses were obtained before
ebruary 10, suggesting that the A/Brisbane/10/2007-like virus 33 (2015) 246–251
was circulating in our study population during the early season,
rather than emerging during or after the epidemic peak. However,
the number of characterized viruses in our study population
was small, and we could not assess changes in the prevalence of
antigenic variant viruses during the season. We cannot rule out
the possibility that antigenic drift contributed to the increased risk
of inﬂuenza with increasing time since vaccination. However, we
would not expect to see differential effects by age group if virus
evolution was the only factor contributing to the changing risk of
inﬂuenza over time.
Evidence from randomized clinical trials suggests that vaccine
induced protection from TIV can diminish within one season, at
least in young children. A re-analysis of three pediatric clinical tri-
als comparing TIV and LAIV has shown that the relative efﬁcacy
of TIV against antigenically similar strains declined with increas-
ing time since vaccination [12]. The relative efﬁcacy of LAIV vs. TIV
for preventing illness due to matched strains increased from 0 to
4 months post-vaccination (range, 25–60%) to >4–8 months post-
vaccination (range, 49–89%). However, similar efﬁcacy was  seen in
each time interval for mismatched strains.
During the 2011–2012 season, observational studies of vaccine
effectiveness against A (H3N2) infections in Europe have also pro-
vided some evidence consistent with waning protection. In the
United Kingdom, adjusted vaccine effectiveness was 53% for indi-
viduals vaccinated less than three months before illness onset, and
12% for those vaccinated three months or more before illness onset
(p = 0.02, test for trend) [7]. In the Navarre region of Spain, adjusted
vaccine effectiveness against A (H3N2) was  61% in the ﬁrst 100
days after vaccination, 39% between 100 and 119 days, and zero
after 120 days [8]. Among patients ≥65 years old, vaccine effec-
tiveness against all inﬂuenza strains was 85% and 24%, respectively,
for those who became ill <100 days after vaccination and 100–119
days after vaccination. However, the sample size was  sparse and the
conﬁdence interval included zero for both estimates. The I-MOVE
project assessed waning immunity during the 2011–2012 season
based on enrollments in eight European Union member states [6].
In a pooled analysis, the adjusted vaccine effectiveness against A
(H3N2) was  46.8% and 10.5%, respectively, among patients with ill-
ness onset less than 93 days after vaccination and those with illness
beginning 93 days or more after vaccination. The interpretation of
waning immunity all three studies was  complicated by the emer-
gence of antigenic variant A (H3N2) viruses in Europe as the season
progressed.
The biologic mechanisms that may  contribute to waning pro-
tection are uncertain, but they likely differ for children and older
adults. Most young children have not been primed by natural
infection and the immune system is immature. In older adults,
immunosenescence occurs with reduced cytotoxicity of natural
killer (NK) cells, reductions in macrophages and dendritic cells,
reduced pathogen sensor expression and function, decreased pools
of naïve T and B cells, and greater numbers of memory and effector
T and B cells [13,14]. It is uncertain how these age-related changes
in immune response might contribute to waning protection over a
period of weeks or months. Although HI antibody titers are main-
tained for several months in older adults, changes in T cell function
may  also inﬂuence the duration of vaccine mediated protection.
Inﬂuenza vaccination stimulates a cellular immune response in the
elderly, and there is some evidence that measures of cellular immu-
nity may  be better correlates of vaccine protection in the elderly
compared to HI antibody titers [15,16]. However, it is not known if
those responses vary over the course of an inﬂuenza season.
The CDC Advisory Committee on Immunization Practices (ACIP)
currently recommends that vaccine providers in the United States
should begin offering vaccination soon after vaccines becomes
available and, if possible, by October [17]. There has been a trend
toward earlier vaccination since the 2009 pandemic, and inﬂuenza
accine
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accines may  be available for administration as early as August [18].
s a result, the interval from vaccination to the peak of the inﬂuenza
eason (i.e., time of highest risk of inﬂuenza exposure) could be as
ong as 7 or 8 months for individuals who are vaccinated very early.
esults from this study, which was restricted to a single community
nd season, do not justify changes to the current recommendations.
owever, the ﬁndings from this study and others indicate the need
or further research on waning protection in different seasons and
opulations.
Strengths of this study include the systematic recruitment from
 population cohort using well-deﬁned screening criteria in the out-
atient and hospital setting, ascertainment of illness onset dates,
se of a highly sensitive and speciﬁc molecular test for inﬂuenza
etection, restriction to a speciﬁc inﬂuenza A subtype, and access
o detailed information on vaccine administration. The major limi-
ations include a relatively small number of cases for age stratiﬁed
nalyses, and the co-circulation of both vaccine matched and anti-
enic variant A (H3N2) viruses in the study population. We  cannot
ule out the possibility of residual confounding due to unmeasured
haracteristics associated both with early vaccination receipt and
isk of inﬂuenza. We  were also unable to assess heterogeneity in
he study population as a potential source of bias. It is uncertain
f the ﬁndings can be generalized to other H3N2 seasons or infec-
ions due to other types or subtypes. Analysis of waning protection
cross multiple seasons was not feasible due to fewer cases in other
easons, changing vaccine formulations, and virus antigenic drift.
In conclusion, we observed a signiﬁcant association with
nﬂuenza A (H3N2) positive medically attended ARI visits with
ncreasing time since vaccination over the course of a single sea-
on in children and older adults. Antigenic drift and host factors
ay  have contributed to this phenomenon, and further research is
eeded to conﬁrm these ﬁndings.
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